Work

SURFactant Administration by SUPraglottic Airway (the SURFSUP 1 Trial): Statistical Analysis Plan

Year: 2026

Type: other

Abstract: The SURFSUP 1 Trial is a multi-centre, unblinded, randomised controlled, non-inferiority trial. The trial is investigating whether supraglottic airway surfactant treatment is non-inferior to minimally invasive surfactant treatment (MIST) provided by laryngoscopy and thin catheter, in preventing mechanical ventilation (MV) or repeat surfactant within 72 hours of randomisation, in preterm infants with a diagnosis of respiratory distress syndrome. The trial aimed to enrol at least 1000 preterm infants in 57 neonatal units in seven countries. Enrolment commenced in February 2021 and was completed in August 2026. Full details of the trial design are available in the trial protocol.RegistrationWHO Universal Trial Number: U1111-1258-2109ANZCTR Trial ID: ACTRN12620001184965

Source: Monash University

DOI: 10.26180/34818255

Authors: Calum Roberts, Joyce E O'Shea, Miranda Davies-Tuck, PETER DAVIS, Peter Dargaville, Kate Hodgson, LOUISE OWEN

Institutions: Monash University, The University of Melbourne, University of Tasmania

Language: English

Topic: Neonatal Respiratory Health Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Health and Medical Research Council

OpenAlex ID: W7223977320

Cites:

Cited by:

Related to: 10